← Every company
Fate Therapeutics Inc Patents
What Fate Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
FATE on carbonthat →Filings on file
29
Granted
0
Still pending
29
Filed under
2 names
29 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| REPROGRAMMING METHODS AND CELL CULTURE PLATFORMSC12N 5/0696, C12N 15/63, C07K 14/4702, C12N 5/0603, C12N 5/0606, C12N 15/86, C12N2501/115, C12N2501/15, C12N2501/235, C12N2501/415, C12N2501/603, C12N2501/724, C12N2501/727, C12N2740/15043Filed as Fate Therapeutics, Inc.2026-04-02Bahram VALAMEHR | pending |
| ENHANCING EFFECTOR CELL DURABILITY AND EFFICACY IN ADOPTIVE CELL THERAPIESA61K 40/4211, A61K 31/454, C07K 14/70578, C12N 5/0636, A61P 35/02, A61P 35/00, A61K2239/10, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/35, A61K 40/30, A61K 40/31, A61K 40/11, A61K 31/635, A61K 31/706, A61K 38/19, A61K 38/2013, A61K 38/2086, A61K 45/06, C07K 14/47, C07K 14/7051, C07K 14/70521, C07K 14/70575, C07K 14/7155, C07K 16/2803, C07K2319/02, C07K2319/03, C12N2501/48, C12N2506/45, C12N2510/00, C12N2740/15041, A61K2300/00Filed as FATE THERAPEUTICS, INC.2025-12-24Eigen PERALTA | pending |
| EFFECTOR CELLS HAVING ENHANCED TARGET CELL RECOGNITIONFiled as FATE THERAPEUTICS, INC.2025-11-06EIGEN PERALTA | pending |
| iPSC-DERIVED NK CELL FOR LYMPHOMA TREATMENTA61P 35/00, A61K 40/4211, A61K2239/48, A61K2239/38, A61K 40/35, A61K 40/00, A61K 40/4217, A61K 40/30, A61K 40/15, A61K 40/31, A61K 31/4184, A61K 31/675, A61K 31/7076, A61K 39/395, A61K 39/3955, C07K 16/2887, C07K2317/24, C07K2317/73, A61K2300/00Filed as FATE THERAPEUTICS, INC.2025-10-06Bahram VALAMEHR | pending |
| ADJUSTABLE GRIP SUPPORT FOR HANDHELD PIPETTEB01L 3/0286, B01L2200/085, B01L2300/123Filed as Fate Therapeutics, Inc.2025-09-26Craig Lawyer | pending |
| CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCSC12N 5/0606, C12N 5/0696, C12N 5/0081, C12N 5/0607, C12N2501/148, C12N2501/15, C12N2501/415, C12N2501/60, C12N2501/602, C12N2501/603, C12N2501/604, C12N2501/605, C12N2501/606, C12N2501/608, C12N2501/727, C12N2501/999, C12N2502/99, C12N2506/1307, C12N2509/10, C12N2533/52, C12N2533/54Filed as Fate Therapeutics, Inc.2025-08-20Bahram Valamehr | pending |
| METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATIONC12N 5/0647, A61P 31/22, A61P 39/06, A61P 7/00, A61P 37/02, A61P 31/12, A61P 31/18, A61P 35/02, Y02A 50/30, A61P 35/00, A61K2239/31, A61K2239/38, A61K 40/10, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 35/28, A61K 35/545, C07K 14/7051, C07K2319/03, C12N2501/10, C12N2501/115, C12N2501/125, C12N2501/14, C12N2501/145, C12N2501/155, C12N2501/165, C12N2501/20, C12N2501/22, C12N2501/2302, C12N2501/2303, C12N2501/2306, C12N2501/2311, C12N2501/235, C12N2501/415, C12N2501/727, C12N2501/999, C12N2506/45, C12N2510/00, C12N2533/90, G01N 33/5073Filed as Fate Therapeutics, Inc.2025-08-08Bahram Valamehr | pending |
| METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATIONC12N 5/0647, A61P 37/02, C12N 5/0018, C12N 5/0607, C12N 5/0636, C12N 5/0646, C12N 5/0662, C12N 5/0696, C12N2500/02, C12N2500/38, C12N2501/10, C12N2501/105, C12N2501/115, C12N2501/125, C12N2501/14, C12N2501/145, C12N2501/155, C12N2501/165, C12N2501/22, C12N2501/23, C12N2501/2302, C12N2501/2303, C12N2501/2306, C12N2501/2307, C12N2501/2311, C12N2501/2315, C12N2501/235, C12N2501/26, C12N2501/40, C12N2501/415, C12N2501/42, C12N2501/727, C12N2501/998, C12N2501/999, C12N2506/02, C12N2506/11, C12N2506/1369, C12N2506/45, C12N2533/52, C12N2533/90Filed as Fate Therapeutics, Inc.2025-07-15Bahram VALAMEHR | pending |
| COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESC12N 5/0636, C12N 5/0646, A61P 37/02, A61P 31/00, A61P 43/00, A61P 37/06, Y02A 50/30, A61P 35/00, A61K2239/55, A61K2239/59, A61K2239/48, A61K2239/38, A61K 40/4205, A61K 40/15, A61K 40/4221, A61K 40/11, A61K 31/436, A61K 31/506, A61K 31/7084, A61K 31/7105, A61K 31/713, A61K 38/2086, A61K 39/0011, A61K 45/06, A61K2039/5156, A61K2039/5158, A61K2121/00, A61K2300/00, C12N2501/06, C12N2501/2312, C12N2501/2315, C12N2501/2318, C12N2501/24, C12N2501/25, C12N2501/727, C12N2501/999, C12N2503/02, C12N2506/02, C12N2506/45, C12N2510/00, G01N 33/505, A61K 35/17Filed as Fate Therapeutics, Inc.2025-03-20Jonathan ROSEN | pending |
| COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USEC07K 16/283, C12N 5/0636, C12N 5/0646, A61P 35/00, A61K2239/30, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/35, A61K 40/30, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 40/50, A61K 40/11, A61K 35/17, A61K 39/3955, A61K 45/06, A61K2121/00, A61K2300/00, C07K 14/5443, C07K 14/7051, C07K 14/70535, C07K 14/7155, C07K 16/2827, C07K 16/2887, C07K2317/622, C07K2317/732, C07K2319/02, C07K2319/03, C12N2506/11, C12N2506/45Filed as Fate Therapeutics, Inc.2025-03-14Bahram VALAMEHR | pending |
| METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATIONC12N 5/0636, C12N 5/069, C12N 5/525, C07K 14/5443, C12M 47/04, C12N 5/0646, C12N2501/155, C12N2501/727, C12N2501/998, C12N2506/45, C12N2510/00, C12N2533/90Filed as FATE THERAPEUTICS, INC.2025-03-13Alec WITTY | pending |
| CELLULAR REPROGRAMMING USING TEMPORAL AND TRANSIENT PLASMID VECTOR EXPRESSION SYSTEMC07K 14/47, C12N 5/0696, A61K 35/12, C07K 14/005, C07K 14/4702, C07K2319/50, C12N 15/85, C12N2501/15, C12N2501/60, C12N2501/727, C12N2506/1307, C12N2510/00, C12N2710/16211, C12N2800/10, C12N2800/106Filed as Fate Therapeutics, Inc.2025-02-07Bahram Valamehr | pending |
| ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOFA61K 39/00, A61K 45/06, C12N 5/0696, C12N2310/20, A61P 35/00, A61K 40/4222, A61K 40/15, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/226, A61K 35/17, A61K 35/545, A61K 38/00, A61K 39/3955, A61K2039/505, A61K2039/507, C07K 14/5443, C07K 14/7051, C07K 14/70535, C07K 14/7155, C07K 16/2896, C07K2317/732, C07K2317/76, C12N 5/0636, C12N 5/0646, C12N 5/0647, C12N 9/22, C12N 15/113, C12N 15/85, C12N 15/907, C12N2506/45, C12N2510/00, C12N2800/80Filed as FATE THERAPEUTICS, INC.2025-01-10Bahram VALAMEHR | pending |
| EFFECTOR CELLS HAVING ENHANCED TARGET CELL RECOGNITIONFiled as Fate Therapeutics, Inc.2024-11-08Eigen PERALTA | pending |
| IPSC-DERIVED T CELLS FOR SOLID TUMOR TREATMENTFiled as FATE THERAPEUTICS, INC.2024-11-07MARTIN HOSKING | pending |
| EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORSA61P 35/00, A61K 35/17, C12N 5/0636, C12N2310/20, A61K2239/58, A61K2239/59, A61K2239/48, A61K2239/49, A61K 40/35, A61K 40/30, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 40/50, A61K 40/11, C07K 14/70503, C07K 14/7051, C07K 14/70535, C07K 14/71, C07K 14/7155, C07K 16/2863, C07K 16/2896, C12N 5/0646, C12N 5/0696, C12N 15/1138, C12N2501/15, C12N2501/2302, C12N2502/30, C12N2506/45, C12N2510/00, C07K 16/2803Filed as FATE THERAPEUTICS, INC.2024-10-16Emily CARRON | pending |
| CELLS HAVING SOLID TUMOR TARGETING BACKBONE AND USE THEREOFC07K 16/32, C12N 5/0634, C12N 5/0636, C12N2310/20, A61P 35/00, A61K2239/39, A61K 40/4205, A61K 40/4202, A61K 40/31, A61K 40/50, A61K 40/11, A61K 39/39558, A61K2300/00, C07K 14/705, C07K 14/7051, C07K 14/71, C07K 14/7155, C07K 14/7158, C07K 16/2896, C07K 16/3015, C07K2317/565, C07K2317/622, C07K2319/02, C07K2319/03, C12N 9/22, C12N 15/11, C12N 15/907, C12N2506/45, C12N2510/00Filed as FATE THERAPEUTICS, INC.2024-10-07Bahram VALAMEHR | pending |
| STEALTH STRATEGY ENGAGING IMMUNE RECOGNITION PATHWAYS FOR USE IN ALLOGENEIC CELL THERAPIESA61K 40/30, C12N 5/0646, A61P 35/02, A61P 35/00, A61K2239/13, A61K 40/35, A61K 40/22, A61K 40/4215, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 31/337, A61K 39/39541, A61K 39/39558, A61K2039/505, A61K2300/00, C07K 14/7051, C07K 14/70535, C07K 14/70596, C07K 16/2803, C07K 16/2896, C07K2317/622, C07K2319/02, C07K2319/03, C12N 5/0636, C12N2506/45, C12N2510/00Filed as FATE THERAPEUTICS, INC.2024-10-04Bahram VALAMEHR | pending |
| ADJUSTABLE GRIP SUPPORT FOR HANDHELD PIPETTEFiled as Fate Therapeutics, Inc.2024-09-27Craig Lawyer | pending |
| IPSC-DERIVED EFFECTOR CELLS FOR AUTOIMMUNE DISEASE TREATMENTFiled as FATE THERAPEUTICS, INC.2024-09-06BAHRAM VALAMEHR | pending |
| SOLID TUMOR TARGETING BACKBONE PROMOTING EFFECTOR CELL DIFFERENTIATION AND FUNCTIONFiled as FATE THERAPEUTICS, INC.2024-07-30EIGEN PERALTA | pending |
| iPSC-DERIVED EFFECTOR CELLS FOR AUTOIMMUNE DISEASE TREATMENTFiled as Fate Therapeutics, Inc.2024-05-08Bahram VALAMEHR | pending |
| ENGINEERED EFFECTOR CELLS FOR TRAFFICKING OF ALLOGENEIC CELL THERAPIES IN SOLID TUMORSA61P 37/02, A61K 40/35, C12N 5/0636, C12N2310/20, A61P 35/00, A61K2239/59, A61K2239/49, A61K2239/39, A61K 40/30, A61K 40/42, A61K 40/31, A61K 40/50, A61K 40/11, C12N 9/226, A61K 31/337, A61K 31/675, A61K 31/7076, C07K 14/7051, C07K 14/70535, C07K 14/70539, C07K 14/70596, C07K 14/715, C07K 14/7155, C07K 14/7158, C07K2319/02, C07K2319/03, C12N 15/11, C12N 15/907, C12N2506/45, C12N2510/00, A61K2300/00Filed as Fate Therapeutics, Inc.2024-05-02Martin HOSKING | pending |
| ENGINEERED EFFECTOR CELLS AND METHODS OF ENHANCING UBIQUITOUS TARGETING OF SOLID TUMORSA61K 40/42, A61K 40/15, A61P 37/00, A61P 31/12, A61P 35/00, A61K2239/28, A61K2239/46, A61K 40/4215, A61K 40/4202, A61K 40/31, A61K 40/421, A61K 40/11, A61K 35/545, A61K 39/3955, A61K 45/06, A61K2300/00, C07K 14/7051, C07K 16/2833, C07K 16/2896, C07K 16/32, C07K2319/03Filed as FATE THERAPEUTICS, INC.2024-05-02John Charles GOULDING | pending |
| EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORSA61K 35/17, A61P 35/00, A61K 40/15, A61K 40/31, A61K 40/11, C07K 14/7051, C07K 14/70535, C07K 14/7155, C12N 5/0636, C12N 5/0646, C12N 5/0696, C12N2501/15, C12N2501/2302, C12N2502/30, C12N2506/45, C12N2510/00Filed as FATE THERAPEUTICS, INC.2024-04-18Emily CARRON | pending |
| IPSC-DERIVED NK CELL FOR LYMPHOMA TREATMENTFiled as FATE THERAPEUTICS, INC.2024-04-05BAHRAM VALAMEHR | pending |
| iPSC-DERIVED EFFECTOR CELLS FOR AUTOIMMUNE DISEASE TREATMENTFiled as Fate Therapeutics, Inc.2024-02-23Bahram VALAMEHR | pending |
| OFF-THE-SHELF IPSC-DERIVED CAR-NK CELL AS MONOTHERAPY AND IN COMBINATION WITH ANTIBODYA61P 35/00, A61K 40/15, A61K 40/31, A61P 37/00, A61K2239/13, A61K2239/21, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/4215, A61K 40/50, A61K 35/17, A61K 39/3955, A61K 45/06, A61K2039/505, A61K2039/545, A61K2039/55, A61K2300/00, C07K 16/2878, C07K 16/2896, C07K2317/32, C07K2317/565, C07K2317/622, C07K2317/732, C07K2319/03, C12N 5/0646, C12N2502/45, C12N2510/00Filed as Fate Therapeutics, Inc.2024-02-16Bahram VALAMEHR | pending |
| COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIESC07K 16/00, C12N 5/0636, Y02A 50/30, A61K2239/48, A61K 40/4254, A61K 40/4219, A61K 40/4232, A61K 40/4211, A61K 40/31, A61K 40/11, A61K 31/444, A61K 31/519, A61K 39/39558, A61K 45/06, C07K 14/7051, C07K 16/2809, C07K2319/03, C07K2319/33, C12N 5/0646, C12N2501/999, C12N2506/02, C12N2506/45, C12N2510/00, G01N 33/5047, G01N2800/7028, A61K2300/00Filed as Fate Therapeutics, Inc.2024-02-14Jonathan ROSEN | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on FATE
Company overviewEverything on FATE in one place, with the price.SEC filingsWhat FATE's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat FATE's own officers and directors buy and sell.Who owns itEvery manager reporting a position in FATE.Funds holding itWhich funds and ETFs hold FATE, and how big a bet.